---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-24-000116"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:12:34.710484+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q2 revenue $114.4M (+27% YoY); net income $5.7M; record test volumes

## Summary
- Total revenue $114.4M (+27% YoY); testing revenue +31%; test volume 39,023 (+23%).
- Net income $5.7M; adjusted EBITDA $24.0M (21% of revenue); generated $26.7M cash.
- Record Decipher Prostate volume ~19,900 (NCCN guideline boost); Afirma volume ~15,700 (new Medicare coverage for Bethesda V).
- Cash and cash equivalents $235.9M; three Decipher studies published including SEER-linked analysis.

## SEC filing metadata
- accession: 0001384101-24-000116
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410124000116/0001384101-24-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410124000116/vcyt-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-24-000116
- JSON: https://secwatch.observer/filing/0001384101-24-000116.json
- Plain text: https://secwatch.observer/filing/0001384101-24-000116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.